Answers are grounded in this paper and cite their sources.
Demonstrates rapid pathogenicity resolution for variants in genomic screening, suggesting improved treatment decisions.
Genomic screening increasingly reveals variants of uncertain significance, forcing clinicians to make high-stakes decisions as million-dollar drug and gene-replacement therapies emerge. Rapid in vivo zebrafish assays can help to resolve variant pathogenicity within weeks, providing organism-level evidence that informs treatment decisions, prevents unnecessary interventions, and strengthens precision medicine.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: